Infliximab biosimilar for psoriasis

Remsima (infliximab), an anti-inflammatory biologic medicine biosimilar to the anti-TNF Remicade (infliximab), has been launched in the UK


Remsima (infliximab), an anti-inflammatory biologic medicine biosimilar to the anti-TNF Remicade (infliximab), has been launched in the UK with a licence for a range of conditions, including psoriasis.
Remsima has been specifically developed to be highly similar to Remicade, which binds and blocks TNF alpha, an inflammatory substance that is overproduced in some inflammatory conditions.
Remsima was authorised by the European Medicines Agency after undergoing a comparability assessment versus Remicade. This included clinical trials involving 850 patients in 20 countries, which the manufacturers claim showed no clinically meaningful differences between the two medicines.
European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment report: Remsima (infliximab)
Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Comorbidities in patients with psoriasis

Comorbidities in patients with psoriasis

Patients with moderate to severe psoriasis are at increased...

Case Reports:  Recurring resolving rash on the dorsum of the foot

Case Reports: Recurring resolving rash on the dorsum of the foot

This patient presented with a localised rash that had...

Psychological care: Quality of life assessment in skin disease

Psychological care: Quality of life assessment in skin disease

Patients should be assessed for the impact on their...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases